- Opinion
- [Reporter’s View] Investors’ money, who is it for?
- by An, Kyung-Jin Oct 21, 2020 06:33am
- The public is giving the cold shoulder to the South Korean bio companies and their recent investments. A number of bio companies have apparently invested in Optimus fund that caused loss of about 500 billion won from an alleged fraud. And as the public found out about the fraud, the bio companies could not avoid their harsh reproach. Onc
- Opinion
- [Reporter's View] Generic substitution is necessary
- by Lee, Hye-Kyung Oct 21, 2020 06:32am
- The activation of generic substitution was a daily issue at the National Assembly Health and Welfare Committee's national audit held on the 7th to 8th and 13th. It has been a long time since 2015 that the National Assembly has been interested in revitalizing alternative preparations as much as this year. This is also the reason why Young-Seo
- Opinion
- [Editor’s View] Why still linger on bioequivalence test?
- by Chon, Seung-Hyun Oct 19, 2020 06:19am
- The South Korean government seems to be still lingering on the notion of restricting the joint bioequivalence test the Regulatory Reform Committee has put a brake on. At the recently convened National Assembly Annual Audit, Minister Lee Eui-kyung of Food and Drug Safety stated that she “fundamentally agrees with the restricting the ‘on
- Opinion
- [Reporter's View] Vaccine's Cold Chain& Distribution System
- by Oct 17, 2020 06:36am
- Shinsung Pharm in charge of distribution of the flu vaccine at room temperature is being criticized. Shinsung Pharm itself has acknowledged the fault in the distribution process and is waiting for the disposal of the health authorities. The pharmaceutical distribution industry, which has been mainly dealing with synthetic drugs and OTC dru
- Opinion
- [Reporter’sView] Revisiting gene list for NGS panel testing
- by Eo, Yun-Ho Oct 12, 2020 06:16am
- Human epidermal growth factor receptor 2 (HER2), anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) would be familiar terms for the people who have been paying a close attention to those news articles regarding anticancer treatment. Depending on the genetic mutation a patient has, effective treatment varies whil
- Opinion
- [Reporter’s view] Nikola and Korean Pharmaceutical Market
- by Kim, Jin-Gu Sep 28, 2020 06:21am
- Money flows into unsubstantiated expectations. Money begets money. The stock value jumped over the moon. Before long, It came to light. Stock prices plummeted, and investors fell into despair. It is a story about the American hydrogen truck company 'Nikola'. It was once called the second Tesla and received the attention of investors, but o
- Opinion
- [Reporter’s Note] Will KRPIA appoint a Korean chairman?
- by Eo, Yun-Ho Sep 21, 2020 06:12am
- While a few multinational pharmaceutical companies have confirmed their foreign executives would be leaving the position, the Korean Research-based Pharmaceutical Industry Association’s (KRPIA) board of director (BOD) is also expected to undergo some changes as well. The two foreign executives bidding farewell are MSD Korea’s CEO Avi B
- Opinion
- [Reporter’s Note] “Loonshots” in new drug development
- by An, Kyung-Jin Sep 18, 2020 06:30am
- I finally caught up to read the bestselling book, “Loonshots” that Bill Gates praised as ‘a book to carry around in your bag to read.’ The book is written by Safi Bahcall, who received a doctorate degree in physics from Stanford University and co-founded ‘Synta Pharmaceuticals.’ The author defines “Loonshots” as “a neglected proje
- Opinion
- [Reporter’s View] A salesperson who lost a place to go
- by Kim, Jin-Gu Sep 4, 2020 06:52am
- "I went to work today, but I was just sitting in the car. I couldn't do anything other than that." Mr. A, who works as a salesperson for a pharmaceutical company in the metropolitan area, complained with frustration. He sat in the car for lunch with kimbap today. He couldn't even go to a cafe. He opened his laptop from the driver's seat, d
- Opinion
- [Reporter’s Note] Why so cautious with all-comers drug?
- by Eo, Yun-Ho Aug 27, 2020 06:24am
- Within the pharmaceutical industry, a drug targeting ‘all-comers’ mean it is indicated to treat all patients in non-specific stages of disease. A drug proving treatment efficacy regardless of receptor or genetic mutation sound interesting and appealing. However, the South Korean government is still conservative on the all-comers drug t
